In addition, the inhibition of estrogen synthesis and signaling by 1,25(OH)2D and its anti-inflammatory actions have been shown to be clinically crucial for inhibiting ER-positive breast cancer by reducing the levels of inflammatory prostaglandins and decreasing estradiol synthesis by aromatase selectively in breast cancer cells [58]. This evidence concerns the gene CYP19A1 and breast cancer.